Counterfeit Ostarine (MK-2866): What Laboratory Testing of Market Products Reveals
Ostarine, also known as MK-2866 or enobosarm, is the most widely sold selective androgen receptor modulator on the grey market. It is also one of the most thoroughly tested by independent laboratories, and the findings are consistently poor. Our editorial team reviews what chemical analyses of market products have shown and why this matters beyond anti-doping.
What ostarine is and its regulatory status
Ostarine is a non-steroidal compound developed to bind the androgen receptor with tissue selectivity, aiming for anabolic effects in muscle and bone with fewer androgenic effects elsewhere. It was investigated by pharmaceutical companies for muscle wasting associated with cancer and for stress urinary incontinence, reaching phase III trials.
It has never received marketing authorisation anywhere. No medicines regulator, including the MHRA, the European Medicines Agency and the US Food and Drug Administration, has approved any SARM for human use. The FDA has issued warning letters and public advisories about products containing them.
In the UK, selling ostarine for human consumption as a supplement is unlawful, since it is an unlicensed medicinal product rather than a food. It is nonetheless widely sold online, often labelled "for research use only" or "not for human consumption" in an attempt to evade regulation.
In sport, ostarine is prohibited at all times under the World Anti-Doping Code in the class of other anabolic agents, and it is among the most frequently reported substances in adverse analytical findings worldwide.
What the laboratory analyses found
Several independent studies have purchased products marketed as SARMs and analysed their contents. The most frequently cited is by Van Wagoner and colleagues, published in JAMA in 2017. The team at the Sports Medicine Research and Testing Laboratory in Utah bought 44 products sold as SARMs online and analysed them with validated methods.
Their findings were striking. Only about half the products contained the SARM stated on the label at a quantity approximating the claim. Roughly four in ten contained a different unapproved drug not listed on the label, around one in ten contained no active compound at all, and a quarter contained substances listed on the label plus others not declared. Measured amounts ranged from a small fraction of the stated dose to several times it.
Subsequent investigations reached similar conclusions. Leaney and colleagues (2021) analysed products purchased in Australia and found frequent substitution and label inaccuracy. Work in Europe and the United States has identified undeclared compounds including other SARMs, the growth hormone secretagogue ibutamoren, the myostatin-pathway agent ACE-031-related substances, aromatase inhibitors, and in some cases classical anabolic steroids.
The reason is structural rather than accidental. These products are manufactured outside any pharmaceutical quality system, with no batch release testing, no stability data and no regulatory oversight of any kind.
| Finding in analysed products | Approximate frequency reported | Consequence for the buyer |
|---|---|---|
| Label-stated compound present at roughly stated amount | About half | Best case; still an unlicensed drug |
| Different unapproved drug substituted or added | Around four in ten | Unknown exposure, unexpected effects |
| No active compound detected | About one in ten | Money lost, placebo exposure |
| Amount substantially different from label | Common | Unpredictable dose, higher risk |
| Undeclared steroids or other agents | Repeatedly reported | Doping violations and additional health risk |
Why this matters for health
Even a correctly labelled ostarine product is an unapproved drug. Clinical trial data and case reports describe effects that deserve attention. Drug-induced liver injury is the best documented: the US LiverTox database and multiple case reports describe cholestatic and hepatocellular injury in users of SARMs, including ostarine, some requiring hospital admission.
Ostarine also suppresses the hypothalamic–pituitary–testicular axis. Phase II trial data reported reductions in total testosterone and sex hormone binding globulin, and clinical case series describe suppressed gonadotrophins in users. Lipid changes, in particular reductions in HDL cholesterol, have also been reported.
When the product contains something else entirely, the risk profile becomes impossible to predict. Undeclared aromatase inhibitors, growth hormone secretagogues or classical steroids bring their own effects, and a user who develops symptoms cannot tell their doctor what they took.
There have also been reports to the FDA's adverse event system and in the medical literature of serious events in SARM users, including liver failure and cardiovascular events. Causality in individual cases is hard to establish, but the pattern is consistent enough that regulators have issued repeated warnings.
The anti-doping dimension
Ostarine has been responsible for a long list of sanctions in athletics, mixed martial arts, cycling, rugby and other sports. Importantly, many athletes have tested positive after taking products that did not declare it on the label.
Contamination can occur at very low levels and still produce a positive test, because modern mass spectrometry detects nanogram-per-millilitre and lower concentrations. Studies of supplement contamination have shown that trace cross-contamination in facilities handling SARMs is sufficient to cause adverse analytical findings.
UK Anti-Doping and the Informed Sport programme both advise athletes that strict liability applies: the athlete is responsible for what is in their body, whatever the label said. Batch-tested products reduce but do not eliminate risk.
For competing athletes, the practical message from the laboratory studies is simple. Any product from the SARM grey market, and any product from a seller who also lists SARMs, should be treated as a serious contamination hazard.
How to think about products and labels
The analyses suggest several points that consumers can usefully bear in mind:
- "For research use only" is a legal disclaimer, not a quality statement. It signals an absence of regulation, not purity.
- Certificates of analysis supplied by the seller prove little unless they come from an accredited independent laboratory, name the batch and can be verified directly with that laboratory.
- Price is not a quality signal. Published analyses found poor-quality products across price points.
- Brand reputation on forums is not evidence. Several products with strong online reputations were among those found to be mislabelled.
- Legitimate medicines carry a product licence number and a patient information leaflet. Nothing in this category does.
Anyone who has used these products and experiences dark urine, yellowing of the skin or eyes, severe fatigue, abdominal pain, swelling or chest symptoms should seek medical attention promptly and say what they have taken. Clinicians need that information and will not report it to anyone.
Suspected adverse reactions and suspect products can be reported in the UK through the MHRA Yellow Card scheme, which accepts reports from members of the public.
For those pursuing muscle and strength goals, the ingredients with real evidence, creatine monohydrate, sufficient protein, caffeine and structured progressive training, remain available, legal and quality-controlled.
Conclusions of the editorial team
The published laboratory evidence on products sold as ostarine is unusually clear. A substantial proportion do not contain what the label says, many contain other unapproved drugs, some contain nothing, and dose accuracy is poor.
This is not a problem that careful shopping solves, because the entire supply chain sits outside pharmaceutical regulation. The buyer's exposure is genuinely unknown.
Added to that is the fact that ostarine itself is an unlicensed drug associated with liver injury, hormonal suppression and adverse lipid changes, and that it is prohibited in sport with a long record of sanctions.
Readers may also wish to read our articles on supplement contamination and inadvertent doping, on liver markers in strength athletes and on how to assess a certificate of analysis.
References
- Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. JAMA. 2017;318(20):2004–2010.
- Leaney AE, Beck P, Biddle S, et al. Analysis of supplements available to UK consumers purporting to contain selective androgen receptor modulators. Drug Test Anal. 2021;13(1):122–127.
- Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women. J Cachexia Sarcopenia Muscle. 2011;2(3):153–161.
- Flores JE, Chitturi S, Walker S. Drug-induced liver injury by selective androgenic receptor modulators. Hepatol Commun. 2020;4(3):450–452.
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Selective androgen receptor modulators. Bethesda: NIDDK; updated 2020.
- Efimenko IV, Valancy D, Dubin JM, Ramasamy R. Adverse effects and potential benefits among selective androgen receptor modulators users: a cross-sectional survey. Int J Impot Res. 2022;34(8):757–761.
- World Anti-Doping Agency. The Prohibited List. Montreal: WADA; current edition.
